Decoy Therapeutics (DCOY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
19 Dec, 2025Executive summary
Supplement updates the definitive proxy statement for the annual meeting adjourned to December 31, 2025.
All prior information in the proxy statement remains unchanged except as noted in this supplement.
Voting matters and shareholder proposals
Annual meeting of stockholders was initially held on December 19, 2025, and adjourned to December 31, 2025.
Board of directors and corporate governance
Alliance Advisors, LLC was engaged as an independent proxy solicitation and advisory firm.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Decoy Therapeutics
- Equity line offering raises up to $5M, with major dilution and liquidity risks for shareholders.DCOY
Registration filing15 Jun 2026 - Shareholders to vote virtually on directors, executive pay, and auditor ratification for 2026.DCOYProxy filing4 Jun 2026
- Annual meeting to vote on directors, executive pay, and auditor, with strong governance and oversight.DCOYProxy filing4 Jun 2026
- Q1 2026 net loss rose to $2.22M as R&D spending surged post-merger; cash funds last into late 2026.DCOYQ1 20268 May 2026
- AI-driven multi-antivirals advance toward clinical trials with major milestones ahead.DCOYStatus update13 Apr 2026
- 2025 net loss rose to $12.5M, with cash runway into late 2026 but going concern risk persists.DCOYQ4 202531 Mar 2026
- Vote on equity plan and reverse split to support Nasdaq listing after merger.DCOYProxy Filing9 Jan 2026
- Key votes on equity plan and reverse split aim to secure Nasdaq listing after Decoy merger.DCOYProxy Filing29 Dec 2025
- Biopharma firm seeks to raise up to $50M for cancer drug development amid significant risks.DCOYRegistration Filing16 Dec 2025